Para-Aminobenzoic Acid (PABA): A Comprehensive Reference
1. Identity, Chemistry, and Natural Sources
Chemical Identity
Para-aminobenzoic acid (PABA) is an aromatic moiety having the molecular formula C7H7NO2, also well known as 4-aminobenzoic acid. Its structure consists of a benzene ring with two functional groups attached at opposite ends: an amino group (–NH2) and a carboxylic acid group (–COOH). The term "para" indicates that these groups are in the 1 and 4 positions on the ring, which is a key feature of its chemical identity. Chemically, it is a white crystalline substance. The compound is also commonly designated as pABA in the biochemical literature and may appear in supplement and pharmaceutical labeling under the synonyms 4-Aminobenzoic Acid, Aminobenzoic Acid, Vitamin B10, Vitamin Bx, Vitamin H1, and Bacterial Vitamin H1.
Vitamin Status
PABA is part of the folic acid molecule. It was once considered a B vitamin but is now considered a nonessential nutrient. PABA is an essential nutrient for plants, bacteria, and some animals, but not for humans.
Occurrence in Nature
PABA is a bifunctional aromatic molecule that occurs naturally via bacterial production in animals' digestive systems and plants' chloroplasts. It is particularly abundant in baker's yeast and brewer's yeast in concentrations ranging from 5 to 100 ppm. Food sources of PABA include liver, brewer's yeast (and unfiltered beer), kidney, molasses, mushrooms, and whole grains. Other food sources of PABA include spinach and oat seeds. Through folic acid breakdown, it is also produced in the human body.
Common Supplement Forms and Preparations
PABA is available in multiple pharmaceutical and dietary supplement forms. It has most often been used by adults in doses of 12 grams by mouth daily in 4 to 6 divided doses, and in children in doses depending on weight. Potassium salt formulations of PABA are most common. As a topical preparation, sunscreens with 1% to 15% PABA have been used. Potassium para-aminobenzoate (Potaba™) is a specialized pharmaceutical preparation classified as an antifibrotic agent. It serves as a therapeutic option for conditions characterized by excessive collagen deposition and tissue induration, and delivers high-dose aminobenzoate potassium, a salt form of PABA, which is a component of the vitamin B complex. By utilizing the salt form, the medication ensures better bioavailability and reduces the acidity associated with pure PABA, although gastric irritation remains a consideration.
2. Historical and Traditional Use
Early Discovery
PABA was mentioned in the chemical literature as early as 1900 by British chemist Walter J. Elliott in an article on reactions of its isomer o-aminobenzoic acid. The same year, it was alluded to by Marston Taylor Bogert and August Henry Gotthelf at Columbia University, also in connection with the ortho isomer. It is not clear how PABA was discovered or first synthesized, other than that it has been known since 1863.
World War II and Post-War Medical Use
The first important clinical use of PABA was evolved during World War II, when it was found to be of value in the treatment of several of the rickettsial diseases. Results were encouraging in a number of diverse conditions of unknown etiology—for example, a beneficial effect was noted in lymphoblastoma cutis, in certain forms of lupus erythematosus, in active dermatomyositis, and in scleroderma. PABA also caused a striking fall in the leukocyte counts of patients with chronic myelogenous leukemia. This early clinical record, reported by Zarafonetis in 1949, forms the historical backbone of PABA's therapeutic reputation in the Western medical tradition.
Sunscreen History
Patented in 1943, PABA was one of the first active ingredients to be used in sunscreen. PABA first appeared as a sunscreen agent after World War II because of its ability to absorb UVB rays. PABA in sunscreen and skincare products was common because of its ability to absorb ultraviolet B (UVB) radiation, thereby protecting the skin from sunburn. Its effectiveness as a chemical UV filter made it a popular ingredient in the mid-20th century.
Use in Hair and Skin Pigmentation
Interest in PABA's effects on hair pigmentation also dates to the early post-war period. A 1950 publication by Zarafonetis documented the darkening of gray hair during para-aminobenzoic acid therapy. Earlier still, a 1942 paper by Sieve described clinical effects of PABA on pigmentation and fertility. Based on one small World War II-era study, PABA was suggested for treating male infertility as well as vitiligo, a condition in which patches of skin lose their pigment, resulting in pale blotches.
Early Use in Fibrotic Conditions
Potassium para-aminobenzoate was introduced as a treatment for Peyronie's disease in 1959. Its use in fibrotic connective tissue disorders including scleroderma, dermatomyositis, and morphea subsequently formed the central focus of mid-20th century clinical interest in PABA as a therapeutic agent.
3. Key Constituents, Biochemistry, and Mechanisms of Action
Role in Folate Biosynthesis in Microorganisms
The folate biosynthesis process begins with two precursors: guanosine triphosphate (GTP) and para-aminobenzoic acid (PABA). GTP provides the pteridine ring structure, while PABA serves as a critical linker molecule. The first condensation reaction is the condensation of pABA with 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine to produce dihydropteroate. The second is the reaction of glutamate with dihydropteroate to form dihydrofolate. pABA itself is synthesized from the pentose phosphate pathway; in this pathway, d-erythrose 4-phosphate is condensed with phosphoenolpyruvate to ultimately lead to chorismate. Chorismate serves as a branching point for the synthesis of the aromatic amino acids (tryptophan, phenylalanine, tyrosine) and pABA.
The Shikimate Pathway
PABA is a precursor of folate, and most microorganisms are able to synthesize it via the shikimate pathway. The shikimate pathway starts from the condensation of glycolysis-derived phosphoenolpyruvate (PEP) and the pentose phosphate pathway-derived erythrose 4-phosphate (E4P) to 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP), and ends with the formation of chorismate, the branching point for the synthesis of each aromatic compound. Three enzymes in the folate biosynthesis pathway are involved in the conversion of chorismate to PABA via 4-amino-4-deoxychorismate (4ADC).
Relevance to Human Biology
Bacteria cannot absorb folic acid, but must make it from PABA, pteridine, and glutamate. For humans, folic acid is a vitamin; we cannot synthesize it. This makes this metabolic pathway a selective target for antimicrobial agents. In the body, PABA plays a role in the synthesis of folic acid by bacteria, which is why some antibiotics (sulfonamides) work by interfering with PABA's utilization, thereby inhibiting bacterial growth. While humans cannot synthesize folic acid directly from PABA, its presence has been explored for various therapeutic applications due to its involvement in metabolic pathways and its antioxidant properties.
UV-Absorbing Mechanism
PABA is a UVB absorber, meaning it can absorb wavelengths between 290 and 320 nm, while still allowing UVA wavelengths between 320–400 nm to pass through, producing a tan. The chemical structure of PABA, with the amino and carboxyl groups being para to each other, allows for easy electron delocalization, which reduces the gap between the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO). This makes it easier for the electrons in PABA to transition to a higher energy state upon absorbing light.
Proposed Anti-Fibrotic Mechanisms
Potassium para-aminobenzoate is considered to exert an antifibrotic effect through an increase in oxygen uptake by the tissues, a rise in the secretion of glycosaminoglycans, and an enhancement of the activity of monoamine oxidases. The monoamine oxidases reduce the formation of serotonin, which is believed to play a leading role in fibrosis. In fibroblast cell cultures, potassium para-aminobenzoate can reduce the formation of collagen. It has been postulated that fibrosis results from an imbalance of serotonin and monoamine oxidase (MAO) mechanisms at the tissue level. Fibrosis is believed to occur when an excessive serotonin effect is sustained over a period of time—this could be the result of too much serotonin or too little MAO activity. Aminobenzoate potassium increases oxygen utilization at the tissue level, and it has been suggested that this increased oxygen utilization could enhance the degradation of serotonin by enhancing MAO activity or other activities that decrease the tissue concentration of serotonin. However, data concerning its mode of action and efficacy are scarce.
4. Scientific Evidence by Area of Use
4.1 Sunscreen / UV Protection
Applying PABA to the skin prevents sunburn. PABA is an FDA-approved sunscreen. PABA is approved by the U.S. Food and Drug Administration (FDA) for use as a sunscreen. PABA seems to be effective during sweating, but not when skin is submerged in water—during swimming, for example. The US FDA regulates PABA use at a maximum of 15% concentration.
Despite its historical prevalence and FDA approval, PABA has largely fallen out of favor in sunscreen formulations. PABA is banned or found unsafe in both Canada and the European Union. Concerns about allergic contact dermatitis, photosensitization, and the availability of alternative UV filters drove this shift. The UV-absorbing mechanism is well-established photochemically, but regulatory acceptability now differs significantly by jurisdiction. The evidence base for topical photoprotection is strong for mechanism but limited by safety concerns that have led to regulatory withdrawal in multiple markets.
4.2 Peyronie's Disease
Peyronie's disease is a localized connective tissue disorder that involves tunica albuginea of the penis, presenting with signs and symptoms including penile curvature, pain on erection, erectile dysfunction, and plaque formation. Potassium para-aminobenzoate (Potaba) is FDA-approved for this indication, and the clinical evidence base is the most developed of any PABA therapeutic application.
In 2005, Weidner conducted a prospective, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of Potaba in the treatment of Peyronie's disease. The 12-month multicenter randomized, placebo-controlled trial found higher response rates with Potaba (about three-quarters of completers) and a significant reduction in plaque size versus placebo, although it did not straighten existing curvature; importantly, it seemed to slow worsening of curvature compared with placebo.
In a separate study, a total of 109 patients with Peyronie's disease were treated with either potassium para-aminobenzoate or combination therapy. Forty-four patients (Group 1) received 3 g of potassium para-aminobenzoate (500 mg capsule) four times daily. In an RCT from 2015 in which 103 men were randomized to POTABA vs. placebo, there was a decrease in plaque size in the POTABA arm but no significant difference in deformity.
Conversely, a smaller preliminary study found less favorable outcomes: after 3 months, there were no significant improvements in clinical outcomes of either group, and among all the patients, 23 stopped taking potassium aminobenzoate (23/31, 74%). The use of this medication has limitations including gastrointestinal trouble, ineffectiveness, too many doses, and high price.
The European Association of Urology guideline for penile curvature gives a grade B recommendation ('based on well-conducted clinical studies, but without randomised clinical trial') of potassium para-aminobenzoate to reduce penile plaque size and pain in Peyronie's disease. Although initial studies showed only a minimal improvement in symptoms of Peyronie's disease with the use of potassium para-aminobenzoate, more recent articles showed a significant reduction in plaque size but no change in pain or improvement of the curvature. These results, although encouraging, will need to be confirmed in future studies.
Overall, the evidence for Potaba in Peyronie's disease is moderate in strength: there are at least two published RCTs with mixed findings, consistent evidence of plaque size reduction, but no demonstrated benefit for penile curvature correction. Tolerability is a significant limiting factor.
4.3 Scleroderma and Connective Tissue Fibrosis
PABA (as potassium para-aminobenzoate) is FDA-approved for scleroderma, with clinical interest dating to early case series from Zarafonetis in the late 1940s. In systemic sclerosis (scleroderma), older retrospective analyses linked Potaba use with softer skin and even better survival, but when a modern double-blind trial put it to the test, Potaba did not outperform placebo on primary outcomes. Although PABA is FDA-approved for scleroderma, there is only limited evidence that it is effective. Some research studies suggest it might help for some symptoms of scleroderma, but the most convincing evidence shows that it does not help.
In vitro, the proliferation of all three cell types (normal skin fibroblasts, scleroderma fibroblasts, and rheumatoid synovial cells) showed dose-dependent inhibition beginning at about 3000 µg/mL. Acid mucopolysaccharide secretion by rheumatoid synovial cells and scleroderma fibroblasts was inhibited even at 100 µg/mL, which is within the therapeutic range. This in vitro work provides a plausible cellular mechanism but does not confirm clinical efficacy in humans.
The evidence for scleroderma is weak overall: FDA-approved status reflects historical use rather than contemporary efficacy standards, and the most rigorous modern trial did not support its use.
4.4 Hair Pigmentation (Gray Hair)
PABA, a natural compound that may be used in vitiligo therapy, is associated with hair hyperpigmentation or repigmentation within 2 to 6 months of beginning high-dose (100–600 mg) oral PABA supplementation. Hyperpigmentation occurs in 6% to 35% of patients using PABA, presenting as a gradual darkening of previously gray hair and progression to black or dark brown color as early as 6 weeks. PABA-induced repigmentation is transient, as the previous gray pigmentation is likely to return shortly following PABA discontinuation.
Evidence is limited; historical reports used 300–600 mg/day and any darkening took months and reversed after stopping. The effect on hair color is preliminary and not supported by controlled clinical trials; the finding is based primarily on observational reports and case series.
4.5 Vitiligo
Based on one small World War II-era study, PABA has been suggested for treating male infertility as well as vitiligo. However, this study did not have a control group, so its results are not meaningful. Ironically, a study also suggests that high dosages of PABA can cause vitiligo. The evidence for PABA in treating vitiligo is therefore very limited—it consists of uncontrolled historical observations, and the risk of paradoxical induction of depigmentation at high doses further complicates the picture.
4.6 Dermatomyositis, Pemphigus, and Other Fibrotic Skin Conditions
PABA is FDA-approved for the skin condition dermatomyositis and for pemphigus. However, there is only limited evidence that it is effective. Potassium aminobenzoate is possibly effective in the treatment of scleroderma, dermatomyositis, morphea, linear scleroderma, and pemphigus. The evidence base for these indications consists largely of early observational data and lacks modern, adequately powered, placebo-controlled trials. Evidence strength is insufficient by contemporary standards.
4.7 Male Infertility
The scientific backing for PABA in male infertility is limited, with many studies dating back several decades and lacking rigorous controls. No modern RCTs have evaluated PABA for this indication. Evidence is inadequate to draw conclusions.
4.8 Rickettsial Infections (Historical)
The first important clinical use of PABA was developed during World War II, when it was found to be of value in the treatment of several of the rickettsial diseases. This historical use predates the availability of modern antibiotics and has not been evaluated in contemporary controlled trials. PABA is not a current standard-of-care treatment for rickettsial diseases.
4.9 Other Proposed Uses
PABA is also used for hardening of skin and connective tissue (scleroderma), aging skin, infertility, and many other conditions, but there is no good scientific evidence to support these uses. Scientists have explored using PABA for other conditions such as arthritis, anemia, constipation, and headaches, but insufficient scientific evidence exists to support these claims.
5. Body Systems and Health Areas
- Integumentary system (skin and hair): UV photoprotection (topical); gray hair re-pigmentation (oral); fibrotic skin disorders including scleroderma, morphea, dermatomyositis, and pemphigus; vitiligo.
- Connective tissue / Urological: Peyronie's disease (fibrotic plaques of the tunica albuginea); general anti-fibrotic applications.
- Microbial folate metabolism: Central intermediate in bacterial, fungal, and plant folic acid biosynthesis via the shikimate pathway; the biochemical basis of the sulfonamide antibiotic class.
- Hematopoietic system (historical): Historical case reports of use in leukemia and anemia; not substantiated by controlled evidence.
- Immune/autoimmune system: Studied in lupus erythematosus and rheumatoid arthritis (early uncontrolled reports only).
- Reproductive system: Historically explored for male infertility; evidence is inadequate.
6. Dosage Forms and Reported Dosages
PABA has most often been used by adults in doses of 12 grams by mouth daily in 4 to 6 divided doses. It has also been used by children in doses depending on weight. Potassium salt formulations of PABA are most common.
In the key Weidner 2005 Peyronie's disease trial, the dose was 12 g/day of potassium PABA in divided doses for up to 12 months, typically split with meals to improve tolerance. A Korean study used potassium aminobenzoate 500 mg capsules, 3 g four times daily.
For gray hair re-pigmentation, historical reports used 300–600 mg/day and any darkening took months and reversed after stopping.
PABA is generally considered safe at dosages up to 400 milligrams daily, with higher doses posing significant risks including severe side effects like liver toxicity.
For sunscreen use, sunscreens with 1% to 15% PABA have been used topically.
7. Safety Considerations and Drug Interactions
General Oral Safety
When taken by mouth, PABA is possibly safe when used appropriately. It is FDA-approved for use and generally well-tolerated. PABA is a non-toxic molecule, easily absorbed in the intestine, and its derivatives are capable of broad biological activities. However, dose-dependent risks become more prominent at the high therapeutic doses used in clinical trials.
Hepatotoxicity
Potassium para-aminobenzoate is an agent used in the treatment of sclerotic diseases including Peyronie's disease of the penis. It has been reported that this medication may have been responsible for cases of acute liver injury. In reported cases, patients enjoyed a full biochemical recovery from hepatitis approximately 4 months after discontinuation of potassium para-aminobenzoate. Taking more than 12 grams per day can cause serious side effects such as liver, kidney, and blood problems.
Topical Reactions
Topical application, particularly in older sunscreen formulations, could cause allergic contact dermatitis, characterized by redness, itching, and rash. Photosensitivity, where the skin becomes more sensitive to sunlight, has also been noted. Some individuals may have an allergic reaction to the topical application of PABA.
Renal Concerns
There is a possibility that taking PABA orally may result in its accumulation inside the kidneys, resulting in further deterioration in the condition of people with kidney problems. Therefore, it is advisable that people with kidney disorders should avoid taking PABA.
Drug Interactions — Sulfonamide Antibiotics (Major)
PABA can decrease the effectiveness of certain antibiotics called sulfonamides. Some of these antibiotics include sulfamethoxazole (Gantanol), sulfasalazine (Azulfidine), sulfisoxazole (Gantrisin), and trimethoprim/sulfamethoxazole (Bactrim, Septra). The mechanism for this interaction is fundamental: sulfonamides inhibit synthesis of folate at two different sites. The sulfonamides are structurally similar to PABA and block the incorporation of PABA into dihydropteroic acid. Exogenous PABA therefore directly competes with and can overcome the antibacterial block imposed by sulfa drugs.
Drug Interactions — Dapsone (Major)
PABA has a major interaction with dapsone (Avlosulfon), which is used as an antibiotic. Para-aminobenzoic acid might decrease the effectiveness of dapsone for treating infections.
Drug Interactions — Cortisone (Moderate)
The body breaks down cortisone to get rid of it. PABA might decrease how quickly the body breaks down cortisone. Taking PABA by mouth and getting a cortisone shot might increase the effects and side effects of cortisone.
Surgical Risk
Using PABA intravenously (by IV) might increase the risk of bleeding during surgery. Stopping PABA 2 weeks before surgery is recommended.
Use in Pregnancy and Pediatrics
The safety of PABA supplements in children and pregnant or breastfeeding women is unknown. These populations are not advised to take PABA orally, but the topical application of the compound is likely safe.
Paradoxical Vitiligo Risk
As noted above under vitiligo evidence, a study suggests that high dosages of PABA can cause vitiligo. This represents an important paradox given that PABA has also been historically proposed as a treatment for that same condition.
Tolerability at High Therapeutic Doses
This drug is costly, can require taking up to 24 tablets daily, and is known for its low tolerability caused by gastrointestinal side effects. Unlike some earlier studies in which potassium para-aminobenzoate was reported to cause fewer side effects, other researchers observed many adverse events and poor compliance.
References
Go back